Your SlideShare is downloading. ×

Conference presentation from #iccs2014 in Noordwijkerhout


Published on

Published in: Science, Technology
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide
  • Is a known primary drug target an off-target for another compound so that this can be repurposed into the indication of the other one
  • Is a known primary drug target an off-target for another compound so that this can be repurposed into the indication of the other one
  • Transcript

    • 1. The impact of large-scale genetic data on drug targets – From 1000 genomes to Drug Discovery Josef Scheiber, PhD 10th International Conference on Chemical Structures 10th German Conference on Chemoinformatics June 1-5 2014, Noordwijkerhout The Netherlands
    • 2. Overview • General Introduction • Approaches taken with learnings and results • Further possibilities
    • 3. Significant unmet medical need 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%  diseases Drugresponserate NSAIDS  80 % response rate Alzheimer  25 % response rate Several thousand diseases without known treatment
    • 4. Biological/Pharmacological Understanding drugs targets pathways diseases
    • 5. Disease understanding getting better and better 2010 1970 1960 1950 Disease of the Blood Leukemia Chronic Leukemia Acute Leukemia Preleukemia Lymphoma Indolent Lymphoma Aggressive Lymphoma Increasing understanding of underlying biology opens up new hypotheses – even/particularly for Cheminformatics! 5 Year Survival ~ 0 % ~ 70% Example: Leukemia and Lymphoma
    • 6. From single targets to …
    • 7. … polypharmacology to…
    • 8. Major driver
    • 9. … individual polypharmacology
    • 10. The human genome contains roughly 3 billion nucleotides and the genomes of any 2 individuals vary in 3 million of them A significant likelihood that individuals respond differently to the same medicine This is rooted in differences for drug absorption, distribution, metabolism and excretion There are ~7 billion human genomes and each responds differently to drugs
    • 11. - Cystic fibrosis caused by defects in the CFTR ion channel (orange in diagram) - Just under 5% of cases are caused by the amino acid glycine being replaced by an aspartate in position 551 of the CFTR protein - patients with this mutation are unable to transport chloride to the CFTR Why this study? A single mutation can have massive impact
    • 12. Example: Carbamazepine/Steven Johnsons Syndrome Courtesy: Dr. Thomas Habif Why this study? A single mutation can have massive impact Difference in European and Korean populations HLA allele B*1502
    • 13. The molecular reason behind From Wei, CY et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome
    • 14. Our large-scale analysis
    • 15. Workflow (simplified) Call Variants for each drug target  Compare intraindividual variability with a focus on binding sites
    • 16. Raw Data Analysis Image Processing and base calling Whole Genome Mapping Alignment to reference genome Variant Calling Detection of genetic variation (SNP, CNV etc.) Annotation Linking variants to biological information BioVariance focus Basic NGS workflow
    • 17. Classes of structural variation Alkan, C. et al. Genome structural variation discovery and genotyping. Nature Reviews Genetics 12, 363-376 (2011). Single Nucleotide Aberrations Single Nucleotide Polymorphisms (SNPs) Single Nucleotide Variations (SNVs) Short Insertions or Deletions (indels) Larger Structural Variations (SVs)
    • 18. Workflow Identify drug targets (primary and off-targets, from DrugBank) Call variations on a per- individuum basis
    • 19. Workflow Analyse mutation rates in the targets and in particular drug binding pockets
    • 20. Example: Donepezil / Acetylcholinesterase • PDB 4EY7 Image extracted from Cheung et al., 2012 [2]
    • 21. Example: Donepezil / Acetylcholinesterase
    • 22. Example: Acetylcholinesterase Integrative Genomics Viewer
    • 23. Not very successful Alignment of the 3D structures of mutant number 52 (yellow) and PDB 4EY7 AChE protein (green). The only changed residue is the Y150 (magenta) to H150 (red). The white surface represents the molecular surface of donepezil.
    • 24. Why is this a bad example? AChE a key enzyme in human biology  these are the most highly conserved, even interspecies  Learning: Look at that stuff before investing time 
    • 25. CFTR • 1000 genomes are not enough for finding these cases
    • 26. SLCO1B1 – Simvastatin example - Mutation 37041T>C or V174A, is a SNP in this gene, which encodes the 'organic anion transporting polypeptide 1B1' (OATP1B1) protein. - found primarily in the liver, it regulates the uptake of numerous drugs and natural compounds. The rs4149056(C) SNP defines the SLCO1B1*5 allele. - This allele described by mentioned amino acid change has reduced uptake/transport activity - Therefore, drugs metabolized by OATP1B1 tend to build up to higher circulating concentrations than they would otherwise
    • 27. SLCO1B1 – Simvastatin example - 17fold higher probability for Rhabdomyolosis for statin patients (6fold if one allele)
    • 28. Ultimately: An individual profile
    • 29. What analyses are enabled? • For Drug Design: Do we work on the „right“ target and specifically on the right pocket to design compounds? • Is there a specific population where the drug will work best? • Are there off-targets that can be problematic in certain cases? • Certainly good for ligand-based approaches as well …
    • 30. Project: Personalized Medicine for children
    • 31. Thank you for your attention! Phone: +49 – 89 – 189 6582 – 80 Garmischer Str. 4/V 80339 Munich / Germany